Share on LinkedInShare on LinkedIn

ARTICLE · 23 JULY 2026

FTC Secures $12 Million In Penalties For Alleged HSR Violation

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

Edwards Lifesciences and Genesis MedTech face a record $12 million penalty for allegedly structuring a transaction to avoid Hart-Scott-Rodino Act filing requirements. The FTC claims the companies split consideration between a direct acquisition and a simultaneous investment to stay below the HSR threshold, raising critical questions about transaction structuring and regulatory compliance in merger reviews.

United StatesAntitrust/Competition Law

In Short

The Development: On July 13, 2026, the Federal Trade Commission ("FTC") announced a proposed settlement with Edwards Lifesciences Corp. ("Edwards") and Genesis MedTech Group Limited ("Genesis"), resolving allegations that the companies violated the Hart-Scott-Rodino ("HSR") Act by failing to report Edwards's proposed acquisition of Genesis's subsidiary JC Medical, Inc. ("JC Medical"). Edwards and Genesis will pay civil penalties of $10 million and $2 million, respectively.

The Context: The government alleges that Edwards structured the transaction to remain below the then-applicable $119.5 million HSR threshold by pairing the cash purchase price with a simultaneous investment in Genesis. The complaint alleges that the Genesis investment was part of the same deal and that sufficient value from that investment should have been attributed to JC Medical, making the transaction reportable.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from